Background and objectives: Candida species are problematic opportunistic pathogens in the hospital setting, where they are frequently associated with opportunistic infections of indwelling medical devices. There are only a few effective classes of antifungal agents currently available, and some species, such as Candida lusitaniae, Candida glabrata and Candida krusei, are intrinsically resistant to some of these drugs, further reducing existing therapeutic options. We have recently developed synthetic, non-amphipathic cationic antimicrobial peptides (CAPs) based on the structure of native hydrophobic membrane-spanning domains of integral membrane proteins. In this article, we report on the activity of these CAPs and new variants thereof against eight Candida species.
Introduction
Candida species are the most common opportunistic fungal pathogens of mammals. Nosocomial fungal infections are associated with high levels of mortality. 1 Incidence of Candida infection has risen markedly in the past few decades, in part due to the heavy use of antibacterial agents combined with the availability of only a limited number of safe, effective antifungal drugs; in part due to the emergence of HIV/AIDS; and in part due to the increased use of immunosuppressive chemotherapeutic regimens. [2] [3] [4] The most common agents used to treat Candida infections are the triazoles (i.e. fluconazole and itraconazole) and the polyenes (i.e. amphotericin B). While fluconazole is considered a safe drug, even at relatively high concentrations, polyenes and to a lesser extent ketoconazole demonstrate toxicity at high doses. 5, 6 Another problem is that development of resistance to one compound often results in cross-resistance to other members of the same class. 7 Some yeast species demonstrate inherently reduced susceptibility to these compounds, for example Candida lusitaniae to amphotericin B and Candida krusei to fluconazole. 8 The widespread use of triazoles for therapy has led to increases in the incidence of these naturally less-susceptible species. 9, 10 The propensity of yeast infections to be associated with medical devices, on which the fungi grow as highly drug-tolerant biofilms, 11, 12 further exacerbates the therapeutic challenge.
We described recently the development of a new class of antimicrobial peptides that were originally designed to mimic transmembrane segments of integral membrane proteins and were tagged with lysine residues to facilitate solubilization in aqueous media. 13 These peptides have a non-amphipathic hydrophobic core segment, which distinguishes them from many natural linear cationic antimicrobial peptides (CAPs) that typically form amphipathic a-helices upon interaction with a hydrophobic membrane environment. These peptides (designated kaxins) have the prototypical structure KKAAAXAAAAAXAAWAAX-AAAKKKK-amide, where X is one of the 20 naturally occurring amino acids. Only those peptides with a core segment above a specific hydrophobicity threshold on the Liu-Deber scale 14 (i.e. those peptides in which position X is occupied by F, W, L, I, M, V, C, Y or A) demonstrated the ability to insert spontaneously into lipid micelles and had antibacterial activity in the micromolar range without toxicity to mammalian cells. We have shown previously that placing all of the K residues on the N-terminus and generating all-D-enantiomeric versions, in combination with decreasing the length of the hydrophobic segment, resulted in shorter (and therefore less expensive) peptides that generally displayed increased antimicrobial activity. 13 In the present work, we tested the antifungal activity of a subset of those peptides previously shown to have good antibacterial activity without mammalian cell cytotoxicity, and new derivatives thereof (Table 1) , against clinical isolates of eight different pathogenic Candida species, specifically Candida albicans, Candida tropicalis, Candida parapsilosis, Candida dubliniensis, Candida glabrata, Candida guillermondii, C. krusei and C. lusitaniae, including strains resistant to fluconazole. The ability of the peptides to kill yeast biofilms was tested, and the time course of peptide killing was determined.
Materials and methods

Strains and growth conditions
Yeast strains of the eight separate Candida species used in this study are listed in Table 2 . These strains include American Type Culture Collection reference strains and clinical isolates obtained from the Clinical Microbiology Laboratory of the Hospital for Sick Children, kindly provided by Dr Susan Richardson. The susceptibility of each strain to fluconazole as determined previously by the Clinical Microbiology Laboratory using NCCLS methodology (standard M27-A2) 15 is indicated in Table 2 . The strains were maintained at -80 C in tryptic soy broth supplemented with 15% glycerol. For experiments (given below), each strain was streaked for single colonies on Mueller-Hinton agar plates and incubated at 37 C overnight.
Peptide synthesis
Peptides were synthesized as described previously 13 using standard Fmoc technology and were purified subsequently using HPLC. The purity of each peptide was verified using mass spectroscopy analysis. Peptides were diluted in stock solutions to 2.6 mg/mL, divided into 500 mL aliquots and stored at -20 C.
Determination of MICs
MICs were determined twice, each time in triplicate, in 96-well polypropylene plates as described previously. 13 The methodology that was used previously to determine bacterial MICs with the same peptides was used to facilitate direct comparisons of peptide efficacy across a broad range of cell types. Briefly, yeast strains were inoculated from fresh plates into Mueller-Hinton broth (MHB) and grown overnight at 37 C with 150 rpm shaking. The cells were harvested by centrifugation and resuspended in fresh MHB to a final concentration of 10 7 cfu/mL, as determined by optical density at 600 nm and viable plate counts. Peptides were serially diluted from 256 to 0.25 mg/L in MHB (190 mL), and 10 mL of standardized yeast suspension was added to each well. Positive controls contained no peptide. Plates were incubated for 18 h at 37 C and the lowest concentration of the peptide preventing growth (indicated by lack of visible turbidity) was recorded. Positive growth controls (no peptide) demonstrated visible turbidity after 18 h at 37 C.
Erythrocyte lysis assay
The propensity of the peptides to cause lysis of erythrocytes was measured as described previously. 13 Each experiment was repeated twice in duplicate. Briefly, freshly collected human erythrocytes were washed and resuspended in sterile PBS (14.4 g NaCl, 0.612 g NaH 2 PO 4 .H 2 O and 2.178 g Na 2 H 2 PO 4 .7H 2 O per litre, pH 7.1) to 4% (v/v). Peptides were diluted in sterile PBS to 1300 mg/L, and 100 mL of the erythrocyte suspension and 100 mL of the peptide solution were added to the wells of a 96-well roundbottomed polypropylene microtitre plate. PBS and 0.1% Triton X-100 were used as agents for 0 and 100% haemolysis, respectively. Plates were incubated for 1 h at 37 C and centrifuged at 1000 g for 5 min. The supernatant (100 mL) was transferred to a 96-well flatbottomed polystyrene plate, and the release of haemoglobin was monitored by measuring the absorbance at 540 nm using a microplate reader.
Time course of killing
To determine the kinetics of peptide killing, selected peptides were diluted in MHB to a final concentration that was twice the previously determined MIC for the strain to be tested. Using 96-well polypropylene plates, 190 mL aliquots of the peptide solution were inoculated with 10 mL of a standardized yeast suspension (10 7 cfu/mL in MHB) of the test organism and the plate was incubated at 37 C with 100 rpm shaking for up to 4 h. Triplicate aliquots were removed at 30 min intervals, serially diluted and plated for the determination of viable counts.
Biofilm killing assay C. albicans and C. tropicalis biofilms were tested for susceptibility to peptide killing using methods adapted from Brooun et al. 16 Each experiment was repeated at least twice in triplicate. Washed overnight cultures of C. albicans (strain CA02045) or C. tropicalis (strain CT72241607) were suspended at a concentration of 10 6 cfu/mL in MHB, and 200 mL aliquots were dispensed into a 96-well polystyrene plate. A corresponding 96-peg lid (Nunc) was immersed in the yeast suspensions to allow the formation of biofilms for 24 h at 37 C, with 100 rpm shaking to provide shear forces. The colonized pegs were rinsed in sterile PBS, pH 7.1, to remove nonadherent cells and were immersed in a second plate containing triplicate aliquots of 200 mL MHB without the peptide (control), dF17-6K or dF21-10K at 5 or 10 times the MIC determined previously for the test strain (Table 2 ). This plate was incubated as described above for 18 h. The pegs were rinsed in sterile PBS to remove non-adherent cells and then immersed in a third plate containing 200 mL of sterile PBS per well. The plate was subjected to 10 min of sonication in a sonicating water bath to dislodge biofilm organisms. 17 Each aliquot was then vortexed (2 min) to minimize cell clumping and serially diluted for viable plate counts.
Results
Modification of peptide sequences
The sequences of peptides tested against the pathogenic yeast strains are shown in Table 1 . In our previous study, 13 the kaxin demonstrating the highest overall activity against both Gramnegative and Gram-positive bacteria was dF17-6K, a 17 amino acid D-enantiomeric peptide with six Lys residues at the N-terminus. A similar peptide containing Arg instead of Lys, dF17-6R, had essentially identical antibacterial activity but a marked increase in mammalian cell cytotoxicity, as measured by increased erythrocyte lysis. The variations introduced for this work were: (i) an increase in the number of Lys residues present on the N-terminus from 6 to 10, to raise the overall positive charge; (ii) substitution of Trp for Phe in the enantiomeric 17mers; and (iii) creation of a peptide containing four residues of the non-natural amino acid norvaline (Nva) in place of Ala. Similar to Val, Nva has a side chain containing three carbons, but they are arranged in a linear, rather than branched, configuration, in effect making the side chain longer.
Activity of optimized peptides against pathogenic yeast species
The MICs of the kaxins against a panel of 37 strains of eight Candida species were determined ( Table 2 ), and the peptides showed activity against C. glabrata and C. krusei, which exhibit intrinsic resistance to fluconazole. With the exception of C. tropicalis, there was little intra-species variation in MIC of the peptides tested. To ensure that alteration of peptide sequences did not result in increased toxicity to mammalian cells, lysis of erythrocytes exposed to the peptides at 650 mg/L was determined as described previously 13 (Table 1) . Most peptides demonstrated very low levels of haemolysis, but magainin and kaxins containing five Trp residues (5W17-6K) or norvaline (dW17-Nva-6K) demonstrated significant haemolytic activity.
Time course of killing of pathogenic yeast
One of the important advantages of antimicrobial peptides over traditional antifungal agents is their ability to cause rapid killing via physical mechanisms, 18, 19 which precludes development of resistance. We tested the time course of killing of fluconazolesusceptible and fluconazole-resistant strains of C. glabrata, C. tropicalis and C. albicans using the most effective non-haemolytic peptides dF21-10K and dF17-6K. Magainin II amide was used as the control peptide. Representative Gram-negative (Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus) bacteria were tested for comparison (data not shown). Figure 1 shows that the kaxins kill more rapidly than magainin II amide. Only C. tropicalis strains were killed (>6 log decrease) by magainin II amide within the 4 h test period (Figure 1a) , whereas a proportion of the C. albicans and C. glabrata cells survived. In contrast, dF21-10K (Figure 1c ) killed >6 logs each of C. tropicalis, C. albicans (both fluconazole-susceptible and fluconazole-resistant strains) and the fluconazole-susceptible strain of C. glabrata within the 4 h test period. Therefore, the kaxins are capable of more rapid and complete killing of yeast than the magainin II control, but there is some strain specificity, since the fluconazole-resistant C. glabrata strain was less susceptible to killing. Helmerhorst et al. 20 showed recently that unlike other yeast and fungal species, C. glabrata was insensitive to killing by the salivary antimicrobial peptides histatin 1, 3, 5 and P-113, and much less susceptible to killing by the amphibian-derived CAPs magainin II and PGLa. Extension of the exposure period or an increase in dose may be required to effect complete killing of more recalcitrant strains.
Effect of antimicrobial peptides on yeast biofilms
Nosocomial fungal infections are frequently associated with medical devices, such as central lines, peritoneal dialysis catheters and urinary catheters, on which the fungi grow as adherent biofilms. 11, 12 Previous studies have shown that growth in biofilms significantly increases resistance of yeast to killing with antifungal compounds. For example, Hawser and Douglas showed that, depending on the drug tested, from 30 to 2000 times the MIC for isogenic planktonic cells was required to reduce the metabolic activity of C. albicans biofilms by 50%. 21 Numerous studies have confirmed the increased antifungal resistance of biofilms formed by several yeast species.
11
Peptides showing the best antifungal activity, dF17-6K and dF21-10K, were tested for their ability to kill pre-formed yeast biofilms. C. albicans and C. tropicalis, two species frequently associated with clinically-significant biofilm infections, were tested for biofilm susceptibility to the peptides. For both peptides, we chose to test the efficacy of 5 and 10 times the previously determined MIC for the strains to be tested, based on previous reports showing increased tolerance of fungal biofilms to antifungal agents. Figure 2 shows that at 5· MIC both peptides effected only small decreases in the numbers of viable cells recovered from the biofilms. At 10· MIC, dF17-6K reduced the number of viable biofilm cells by 2-3 logs, but dF21-10K was more effective, completely eradicating pre-formed yeast biofilms containing >10 5 viable cells.
Discussion
In this work, we have shown that kaxins, as non-amphipathic cationic peptides, can kill clinical isolates of a wide range of pathogenic yeast species when applied at micromolar concentrations. Importantly, there was little difference in the MIC required to kill fluconazole-resistant strains compared with fluconazolesusceptible strains of the same species, suggesting that these peptides can be useful in the treatment of infections caused by strains that are less effectively treated with triazoles. Although in their current form this class of peptides has modest potency compared with small molecule drugs, with average MIC values in the 16-64 mg/L range for most strains, they may offer a basis for development of alternatives to traditional antifungal agents. Another important consideration is the potential for cytotoxicity to mammalian cells. Peptides containing five Trp residues (5W17-6K) or norvaline (dW17-Nva-6K) were haemolytic, as was the well-studied control peptide magainin II amide, making them less suitable for use as therapeutics even though the norvaline-containing peptide had good MICs of 4-64 mg/L for the Candida strains tested. The best non-haemolytic peptide in the group tested, dF21-10K, demonstrated good killing kinetics, eradicating five of the six yeast strains tested in 4 h, including a highly Figure 2 . Killing of biofilms by peptides. Biofilms of either C. albicans (strain CA02045) or C. tropicalis (strain CT72241607) were permitted to form on polystyrene pegs for 24 h as described in the Materials and methods section, prior to 18 h of exposure to 5· or 10· the previously determined MIC of the test peptide for each strain (see Table 2 ). Results are the average of two separate experiments performed in triplicate. Asterisks indicate no growth at any dilution on viable plate counts.
fluconazole-resistant strain of C. albicans. Notably, this peptide had good activity against C. glabrata, a species known to exhibit intrinsic resistance to both triazoles and host antimicrobial peptides, 20, 22 although, for reasons that are currently unknown, it was less effective against a strain with documented high-level fluconazole resistance. At 10· MIC, this peptide also killed preformed biofilms of C. albicans and C. tropicalis, two yeast species commonly isolated in the hospital setting. This represents true killing of the biofilm organisms, rather than dispersal, as the surrounding liquid medium was also sterilized (not shown). While consistent with the requirement for higher doses of antimicrobial agents due to the increased tolerance of biofilm organisms, the increased amount of peptide required for eradication was less than the 30-2000· MIC required for small molecule antifungals to kill biofilms. 11 In the future, it may be possible to reduce the amount of peptide required by attaching the peptides directly to the surface of biomaterials to prevent biofilm formation at the stage of initial microorganism attachment. This strategy has been shown to be successful for long-chain hydrophobic polycations, which are chemical mimics of antimicrobial peptides. 23 The technology for attachment of functional peptides to surfaces already exists, 24 and we are currently adapting it for use with antimicrobial peptides.
With regard to peptide composition, increasing the number of K residues on the N-terminus from 6 to 10 (compare dF17-6K with dF21-10K) appears to improve the ability of the peptides to kill Gram-positive bacteria and yeast while slightly decreasing the activity against Gram-negative bacteria, without altering the cytotoxicity of the peptide towards eukaryotic cells, based on a lack of increase in erythrocyte lysis. This result suggests that the increase in positive charge may improve interaction with-and/or promote penetration of-thick yeast cell walls. This improved dF21-10K peptide also shows good activity against important antibiotic-resistant Gram-positive bacteria, including methicillinresistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE). MICs were 32-64 mg/L for MRSA and 32 mg/L for VRE (five strains of each tested, data not shown), the same concentration range that is effective against yeast. Therefore, these peptides show promise as the basis for development of novel, broad-spectrum antimicrobial agents.
